HC Wainwright reaffirmed their buy rating on shares of Oxford Biomedica (OTCMKTS:OXBDF) in a research report report published on Wednesday, The Fly reports.
A number of other equities research analysts also recently commented on OXBDF. Zacks Investment Research downgraded shares of Oxford Biomedica from a buy rating to a hold rating in a research report on Wednesday, August 11th. Royal Bank of Canada reaffirmed an outperform rating on shares of Oxford Biomedica in a research report on Monday, June 21st. Finally, Panmure Gordon raised shares of Oxford Biomedica from a hold rating to a buy rating in a research report on Wednesday, July 7th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Buy and an average price target of $21.00.
OTCMKTS:OXBDF opened at $21.39 on Wednesday. The company has a current ratio of 2.06, a quick ratio of 1.93 and a debt-to-equity ratio of 0.08. Oxford Biomedica has a 12 month low of $10.13 and a 12 month high of $22.86. The company has a market cap of $1.64 billion, a PE ratio of -213.90 and a beta of 1.16. The company has a 50 day simple moving average of $19.52 and a two-hundred day simple moving average of $17.02.
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes.
Further Reading: What is the Fibonacci sequence?
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.